- Home
- CFBK vs BNR Comparison
CFBK vs BNR Comparison
Compare CFBK & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CFBK | BNR |
|---|---|---|
| Founded | 1892 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.4M | 216.9M |
| IPO Year | 1998 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CFBK | BNR |
|---|---|---|
| Price | $33.20 | $32.53 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $29.00 | N/A |
| AVG Volume (30 Days) | ★ 56.4K | 25.2K |
| Earning Date | 02-05-2026 | 03-24-2026 |
| Dividend Yield | ★ 1.08% | N/A |
| EPS Growth | ★ 30.58 | N/A |
| EPS | ★ 2.69 | N/A |
| Revenue | $52,703,000.00 | ★ $75,749,382.00 |
| Revenue This Year | $32.28 | $136.32 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.38 | ★ N/A |
| Revenue Growth | ★ 16.91 | 5.56 |
| 52 Week Low | $19.23 | $2.18 |
| 52 Week High | $33.60 | $41.72 |
Technical Indicators
Market Signals| Indicator | CFBK | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 85.28 | 53.35 |
| Support Level | $28.45 | $29.50 |
| Resistance Level | $29.95 | $41.09 |
| Average True Range (ATR) | 0.95 | 4.03 |
| MACD | 0.37 | -0.75 |
| Stochastic Oscillator | 85.71 | 24.17 |
Price Performance
Historical ComparisonAbout CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.